LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

LLY

984.02

-1.85%↓

JNJ

201.6

-1.57%↓

ABBV

222.42

-0.37%↓

UNH

322.88

-0.38%↓

AZN

90.6

-0.22%↓

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

13.61 -2.65

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.59

Massimo

13.93

Metriche Chiave
By Trading Economics
Entrata	222M 227M
Vendite	-23M 139M
P/E Media del settore	5.298 77.671
Margine di Profitto	163.843
Dipendenti	1,780
EBITDA	6.3M 1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+38.03% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-261M 2.5B
Apertura precedente	16.26
Chiusura precedente	13.61

Notizie sul Sentiment di mercato

By Acuity

50%

182 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

14.24 / 14.78 Supporto e resistenza

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 dic 2025, 22:13 UTC

Utili

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Utili

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Acquisizioni, Fusioni, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

I principali Market Mover

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Utili

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Discorsi di Mercato

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Discorsi di Mercato

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Discorsi di Mercato

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Utili

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Utili

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Utili

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

38.03% in crescita

Previsioni per 12 mesi

Media 19.38 USD 38.03%

Alto 25 USD

Basso 13.75 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

2 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 2 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

14.24 / 14.78Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

182 / 374 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.